|Year : 2022 | Volume
| Issue : 1 | Page : 108-112
Immunotherapeutic potential of n-terminally formylated ESAT-6 protein in murine tuberculosis
Shabir Ahmad Mir1, Sadhna Sharma2
1 Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India; Department of Medical Laboratory Sciences, College of Applied Medical Science, Majmaah University, Al Majmaah, Saudi Arabia
2 Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
|Date of Submission||18-Dec-2021|
|Date of Decision||20-Jan-2022|
|Date of Acceptance||24-Feb-2022|
|Date of Web Publication||12-Mar-2022|
Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012
Shabir Ahmad Mir
Department of Medical Laboratory Sciences, College of Applied Medical Science, Majmaah University, Al Majmaah
Source of Support: None, Conflict of Interest: None
Background: The early secreted antigenic target-6 kDa (ESAT-6) being one of the important antigens expressed by Mycobacterium tuberculosis (MTB) has been widely investigated for its strong immunmodulatory effects. We have previously evaluated the immunotherapeutic efficacy of ESAT-6 in the murine model of experimental tuberculosis (TB). Now in the present study, we have evaluated the immunotherapeutic efficacy of N-terminally formylated form of ESAT-6 (f-ESAT-6) in murine TB. Materials and Methods: The production and purification of f-ESAT-6 have been discussed in our earlier report (Mir SA and Sharma S, 2014). In the present study, the MTB H37Rv-infected mice were treated with f-ESAT-6 alone or in combination with anti-TB drugs (ATDs). Four weeks postinitiation of the treatment, the experimental mice were sacrificed, and the colony-forming units (CFUs) were enumerated in their lungs and spleen as described in “materials and methods” section. Results: The N-terminally formylated ESAT-6 protein (f-ESAT-6) induced a moderate reduction in the bacterial load in the target organs of infected mice. Compared to the dimethyldioctadecyl ammonium bromide treated and untreated groups, the f-ESAT-6 treatment significantly reduced the CFU in the spleen and lungs of infected mice by 0.377 log10 units (P < 0.05) and 0.396 log10 units (P < 0.01), respectively. The administration of f-ESAT-6 in combination with ATDs revealed an additional immunotherapeutic effect and elicited higher therapeutic efficacy over drugs (ATDs) alone. Conclusion: The results of the present study clearly indicate that f-ESAT-6 protein alone as well as in combination with the conventional ATDs induce moderate therapeutic effect against experimental TB.
Keywords: Anti-tuberculosis drugs, colony-forming unit, histopathology, immunotherapy, N-formylated-early secreted antigenic target-6, tuberculosis
|How to cite this article:|
Mir SA, Sharma S. Immunotherapeutic potential of n-terminally formylated ESAT-6 protein in murine tuberculosis. Int J Mycobacteriol 2022;11:108-12
|How to cite this URL:|
Mir SA, Sharma S. Immunotherapeutic potential of n-terminally formylated ESAT-6 protein in murine tuberculosis. Int J Mycobacteriol [serial online] 2022 [cited 2022 May 21];11:108-12. Available from: https://www.ijmyco.org/text.asp?2022/11/1/108/339519
| Introduction|| |
Tuberculosis (TB) remains to be a prominent cause of worldwide morbidity and mortality. According to the World Health Organization Global TB Report 2018, an estimated 10 million individuals became ill with TB and 1.6 million died from the disease in 2017., Currently, Bacillus Calmette-Guerin (BCG) is the only available vaccine against TB with limited protective efficacy ranging from 0% to 80% across different regions. Moreover, the rise of multi-drug resistant and extremely drug-resistant strains of Mycobacterium TB (MTB) have further worsened the control of this disease. Therefore, the development of therapies other than traditional pharmacotherapy is highly needed for improved treatment of TB, especially the drug-resistant TB. One of these alternative therapies is immunotherapy. Host immunity holds great significance for efficiently inhibiting the growth of intracellular pathogens including MTB. Indeed, immunotherapy can improve the treatment of TB by augmenting host immunity to get rid of the bacteria and to shorten the lengthy chemotherapy needed for TB patients.,,,,,,
The early secreted antigenic target-6 (ESAT-6) being one of the significant antigens expressed by MTB has been widely investigated for its strong immunomodulatory effects as a subunit vaccine.,,, Recombinant BCG that exports/secretes ESAT-6 enhances defence against TB in the animal model.,,, Recently, it has been demonstrated that the Mycobacterium bovis live-attenuated vaccine with deletion of esat6 and cfp10 genes failed to confer protection against virulent M. bovis challenge in a mouse model of TB. In addition, ESAT6 DNA vaccines have been reported to possess immunotherapeutic as well as immunoprotective effects in the mice model of TB.,,,
In addition, we have previously evaluated the immunotherapeutic efficacy of ESAT-6 in the murine model of TB. Immunotherapy of MTB-infected mice with recombinant ESAT-6 significantly reduced the bacteria loads in the target organs (lungs and spleen) and fetched additional therapeutic effect to the anti TB drugs (ATDs) when given in combination. We also reported the moderate immunotherapeutic effect of synthetic N-terminal formylated peptide of ESAT-6 in murine TB. Here, in this study, we evaluated the immunotherapeutic efficacy of N-terminally formylated recombinant ESAT-6 protein (f-ESAT-6) against TB infection in mice.
| Methods|| |
Animals and bacterial culture
Balb/c mice (aged 6–8 weeks) and MTB H37Rv used in this study were maintained as reported earlier.,,
N-terminal formylation of early secreted antigenic target-6 and its purification
Expression and N-terminal formylation of ESAT-6 as well as its purification was performed as described previously.
Preparation of a mouse model of tuberculosis and treatment
Naive Balb/c mice were infected with MTB H37Rv and the infection was confirmed as described earlier.,,
After confirmation of the infection, the MTB infected mice were distributed into five groups (n = 6/group) and treated with different formulations [Table 1]. The f-ESAT-6 protein was subcutaneously given at a dose of 30 μg emulsified in 250 μg of dimethyldioctadecyl ammonium bromide (DDA) (three doses/animal at 10 days interval). The anti-tubercular drugs were given orally for 4 weeks on the daily basis as explained elsewhere.,,
Bacterial enumeration and histopathological examination of lungs
Four weeks posttreatment initiation, the lungs and spleens were removed aseptically from the sacrificed mice. The bacterial enumeration and histopathological examination of lungs was performed as reported earlier.,,
The colony-forming units (CFU) data are expressed as mean ± standard error of the mean the comparison between the groups was accomplished using student's t-test. The difference was considered significant at P values less than 0.05 (P < 0.05).
| Results|| |
Cloning and N-terminal formylation of early secreted antigenic target-6
We have previously reported the data related to cloning and N-terminal formylation of ESAT-6 as well as the purification of the f-ESAT-6.
Therapeutic efficacy of f-early secreted antigenic target-6 protein in terms of colony-forming units reduction
The MTB H37Rv infected mice were treated with different formulations as described in earlier sections. In comparison with the untreated infected mice, no reduction in the bacterial load was observed in the DDA treated group (P > 0.05). However, compared to the DDA treated and untreated groups, the f-ESAT-6 treatment significantly reduced the CFU in spleen and lungs of infected mice by 0.377 log10 units (P < 0.05) and 0.396 log10 units (P < 0.01), respectively. The treatment of infected mice with anti-tubercular drugs reduced CFU in respective organs by 1.681 and 2.316 log10 units (P < 0.001) [Figure 1] and [Table 2]. The administration of f-ESAT-6 in combination with ATDs revealed an additional immunotherapeutic effect and elicited higher therapeutic efficacy over drugs (ATDs) alone. The f-ESAT-6 in combination with ATDs significantly reduced the CFU in lungs by 2.757 log10 units (P < 0.001) and in spleen by 2.114 log10 units (P < 0.001) when compared to the DDA treated animals [Figure 1] and [Table 2]. Further, in comparison to the ATD treated mice, the ATD + f-ESAT-6 combination significantly reduced the CFU in the spleen by 0.432 log10 units (P < 0.05) and in lungs by 0.440 log10 units (P < 0.05) [Figure 1] and [Table 2].
|Figure 1: Therapeutic efficacy of recombinant f-early secreted antigenic target-6 alone or in combination with anti-tuberculosis drugs: (a) In lungs; (b) in spleen. Results expressed as mean of log10 colony-forming units ± standard error of the mean of six mice per group. *P < 0.05, **P < 0.01, ***P < 0.001compared to Dimethyldioctadecyl ammonium bromide treated group and #P < 0.05 compared to anti-tuberculosis drugs treated group. CFU: Colony-forming unit, ATDs: Anti-tuberculosis drugs, DDA: Dimethyl dioctadecyl ammonium bromide, f-ESAT-6: N-terminally formylated ESAT-6, SEM: Standard error of the mean|
Click here to view
|Table 2: Bacterial colony-forming unit in the lung and spleen of Mycobacterium tuberculosis infected Balb/c mice after immunotherapy and/or short-term chemotherapy|
Click here to view
Effect of f-early secreted antigenic target-6 immunization on lung pathology of Mycobacterium tuberculosis infected mice
On histopathological analysis, tuberculous lesions, causing consolidation in the lungs of the untreated infected mice, were observed. In comparison, we observed total clearance of the tuberculous lesions in the lung sections of ATD treated as well as ATD plus f-ESAT-6 treated infected mice [Figure 2].
|Figure 2: Histopathological alterations in lungs of experimental mice. Representative photomicrographs [H and E, ×20] of lung tissues of mice in each group: (i) Dimethyldioctadecyl ammonium bromide treated; (ii) f-early secreted antigenic target-6 treated; (iii) anti-tuberculosis drugs treated; (iv) anti-tuberculosis drugs + f-early secreted antigenic target-6 treated. ATDs: Anti-tuberculosis drugs, H and E: Hematoxylin and eosin, DDA: Dimethyldioctadecyl ammonium bromide, f-ESAT-6: N-terminally formylated ESAT-6|
Click here to view
| Discussion|| |
TB is a worldwide threat to human health. There is an urgent necessity to develop novel treatment therapies for TB. Therapeutic vaccines have the potential to defend against TB by provoking the protective immunity of the host. These vaccines can overcome the drug resistance issues and will also help to shorten the duration of TB treatment.,,
It is well established in the literature that ESAT6, an immuno-dominant antigen of M. tuberculosis, can induce potent T-cell stimulation and provide protection against TB.,,,, ESAT-6-induces apoptosis in macrophages and the fusion protein consisting of Ag85B and ESAT6 has been reported to induce long-lasting immune memory against MTB in mice., In our previous study, we evaluated the recombinant ESAT-6 protein for its therapeutic efficacy in murine TB. The recombinant ESAT-6 protein induced moderate adjunctive immunotherapeutic effect in the mouse model of experimental TB. The current study demonstrates the immunotherapeutic efficacy of N-terminally formylated form of ESAT-6 protein (f-ESAT-6). We have previously reported the cloning and expression of ESAT-6 gene (Rv3875) in Escherichia More Details coli and the protocol for N-terminal formylation of the ESAT-6 as well as the production of N-formylated ESAT-6 has also been reported therein.
In the present study, we now demonstrate the therapeutic efficacy of the f-ESAT-6 protein in MTB infected mice. Immunotherapy with f-ESAT-6 moderately decreased the bacterial load in spleen (P < 0.05) and lungs (P < 0.01) of infected mice [Figure 1] and [Table 2]. Further, f-ESAT-6 immunotherapy resulted in an additional therapeutic outcome when combined with short-term chemotherapy (P < 0.05) [Figure 1]. The results of this study show that f-ESAT-6 protein can act as an adjunct to the available anti-TB chemotherapy and help in shortening the treatment period of TB patients. The immunotherapeutic efficacy of f-ESAT-6 was further confirmed by the histopathological analysis of lungs of the experimental mice [Figure 2]. However, the immunotherapeutic efficacy of f-ESAT-6, although insignificantly, but was lower than its nonformylated form (ESAT-6), the data for which has already been published.
| Conclusion|| |
Our results show that N-terminally formylated ESAT-6 alone or in combination with the conventional ATDs induce moderate immunotherapeutic effect against experimental TB. Its therapeutic efficacy could be improved further by using adjuvants that are more efficient.
Compliance with ethical standards
The animal handling protocol was approved in the 39th meeting of the Institutional Animal Ethics Committee (IAEC) of PGIMER with IAEC number 140.
Financial support and sponsorship
This study was financially supported by Indian Council of Medical Research, New Delhi, India.
Conflicts of interest
There are no conflicts of interest.
| References|| |
Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: Are-estimation using mathematical modelling. PLoS Med 2016;13:e1002152.
Anderson EJ, Webb EL, Mawa PA, Kizza M, Lyadda N, Nampijja M, et al.
The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. Vaccine 2012;30:2083-9.
Cooper AM, Khader SA. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev 2008;226:191-204.
Dlugovitzky D, Stanford C, Stanford J. Immunological basis for the introduction of immunotherapy with Mycobacterium vaccae
into the routine treatment of TB. Immunotherapy 2011;3:557-68.
Roy E, Lowrie DB, Jolles SR. Current strategies in TB immunotherapy. Curr Mol Med 2007;7:373-86.
Johnson BJ, Estrada I, Shen Z, Ress S, Willcox P, Colston MJ, et al.
Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients. Infect Immun 1998;66:2426-33.
Wang CC, Rook GA. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae
. Immunology 1998;93:307-13.
Hernández-Pando R, Aguilar D, Orozco H, Cortez Y, Brunet LR, Rook GA. Orally administered Mycobacterium vaccae
modulates expression of immunoregulatory molecules in BALB/c mice with pulmonary tuberculosis. Clin Vaccine Immunol 2008;15:1730-6.
Silva CL, Bonato VL, Coelho-Castelo AA, De Souza AO, Santos SA, Lima KM, et al.
Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice. Gene Ther 2005;12:281-7.
Hamasur B, Haile M, Pawlowski A, Schroder U, Kallenius G, Svenson SB. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F (ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis
. Clin Exp Immunol 2004;138:30-8.
Bai Y, Xue Y, Gao H, Wang L, Ding T, Bai W, et al.
Expression and purification of Mycobacterium tuberculosis
ESAT-6 and MPT64 fusion protein and its immunoprophylactic potential in mouse model. Protein Expr Purif 2008;59:189-96.
Li W, Deng G, Li M, Zeng J, Zhao L, Liu X, et al.
A recombinant adenovirus expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis
elicits strong antigen-specific immune responses in mice. Mol Immunol 2014;62:86-95.
Sharma B, Dua B, Joshi B. Investigating role of Mycobacterium tuberculosis
secretory antigens in altering activation of T cell signaling events in Jurkat T cells. Int J Mycobacteriol 2020;9:405-10.
] [Full text]
Hasan Z, Rao N, Salahuddin N, Ashraf M, Islam M, Jamil B. Measurement of ESAT6-induced IFNγ responses adjunct with CXCL9 increases the rate of diagnosis of active tuberculosis in an endemic region. Int J Mycobacteriol 2013;2:135-40. [Full text]
Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, et al.
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003;9:533-9.
Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 2001;69:2773-8.
Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 2004;72:6148-50.
Langermans JA, Doherty TM, Vervenne RA, van der Laan T, Lyashchenko K, Greenwald R, et al.
Protection of macaques against Mycobacterium tuberculosis
infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 2005;23:2740-50.
GarcIa EA, Blanco FC, Muñiz XF, Eirin ME, Klepp LI, Bigi F. Elimination of ESAT-6 and CFP-10 from a candidate vaccine against bovine tuberculosis impaired its protection efficacy in the BALBc mouse model. Int J Mycobacteriol 2020;9:417-21.
Lowrie DB, Tascon RE, Bonato VL, Lima VM, Faccioli LH, Stavropoulos E, et al.
Therapy of tuberculosis in mice by DNA vaccination. Nature 1999;400:269-71.
Fan X, Gao Q, Fu R. DNA vaccine encoding ESAT-6 enhances the protective efficacy of BCG against Mycobacterium tuberculosis
infection in mice. Scand J Immunol 2007;66:523-8.
Skjøt RL, Oettinger T, Rosenkrands I, Ravn P, Brock I, Jacobsen S, et al
. Comparative evaluation of low-molecular-mass proteins from Mycobacterium tuberculosis
identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun 2000;68:214-20.
Wang QM, Sun SH, Hu ZL, Yin M, Xiao CJ, Zhang JC. Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting. Vaccine 2004;22:3622-7.
Mir SA, Verma I, Sharma S. Immunotherapeutic potential of recombinant ESAT-6 protein in mouse model of experimental tuberculosis. Immunol Lett 2014;158:88-94.
Mir SA, Sharma S. Immunotherapeutic potential of N-formylated peptides of ESAT-6 and glutamine synthetase in experimental tuberculosis. Int Immunopharmacol 2014;18:298-303.
Mir SA, Sharma S. Immunotherapeutic potential of an N-formylated peptide of Listeria monocytogenes
in experimental tuberculosis. Immunopharmacol Immunotoxicol 2019;41:292-8.
Mir SA, Sharma S. Cloning, expression and N-terminal formylation of ESAT-6 of Mycobacterium tuberculosis
H37Rv. Protein Expr Purif 2013;92:223-9.
Cardona PJ, Amat I, Gordillo S, Arcos V, Guirado E, Díaz J, et al.
Immunotherapy with fragmented Mycobacterium tuberculosis
cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 2005;23:1393-8.
WHO. Report of the Expert Consultation on Immunotherapeutic Interventions for Tuberculosis. Geneva: WHO; 2007.
Sheikh JA, Khuller GK, Verma I. Immunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapy. J Immune Based Ther Vaccines 2011;9:4.
Brodin P, Majlessi L, Brosch R, Smith D, Bancroft G, Clark S, et al.
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti
vaccine that induces T cell immunity against region of difference 1 antigens. J Infect Dis 2004;190:115-22.
Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis
. Infect Immun 2000;68:791-5.
Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis
and boosts prior Bacillus
Calmette-Guerin immunity. J Immunol 2006;177:6353-60.
Dong H, Stanek O, Salvador FR, Länger U, Morillon E, Ung C, et al.
Induction of protective immunity against Mycobacterium tuberculosis
by delivery of ESX antigens into airway dendritic cells. Mucosal Immunol 2013;6:522-34.
Olsen AW, Hansen PR, Holm A, Andersen P. Efficient protection against Mycobacterium tuberculosis
by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol 2000;30:1724-32.
Derrick SC, Morris SL. The ESAT6 protein of Mycobacterium tuberculosis
induces apoptosis of macrophages by activating caspase expression. Cell Microbiol 2007;9:1547-55.
You Q, Wu Y, Jiang D, Wu Y, Wang C, Wei W, et al.
Immune responses induced by heterologous boosting of recombinant Bacillus
Calmette-Guerin with Ag85B-ESAT6 fusion protein in levamisole-based adjuvant. Immunol Invest 2012;41:412-28.
[Figure 1], [Figure 2]
[Table 1], [Table 2]